

## Index

- acamprosate, 134–135  
 activation likelihood estimation (ALE), 100  
 acute withdrawal, 85–86  
 addiction  
   behavioral definition of, 4, 12–14  
   behavioral progression of, 9–10  
   and causality, 156–157  
   chemical, 6–12  
   as chronic brain disease, 130–132  
   classification systems of, 6–9  
   clinical definition/diagnosis of, 2, 6–9  
   dark side of, 90–91  
   demography of, 5  
   mental disorders and, 4  
   phenomenology of, 4  
   rates of, 1, 149  
   stigma of, 5–6  
 addiction theories  
   allostatic, 36–38  
   brain disease model, 9–12  
   cue-elicited craving, 40  
   future of, 40–41  
   impaired response inhibition and salience  
     attribution syndrome (iRISA), 38–40  
   incentive sensitization, 34–36  
 adolescence, 127, 149–150  
 Adolescent Brain Cognitive Development  
   (ABCD) study, 32  
 agonists, 66  
 Aharonovich, E., 140  
 Ahmed, S. H., 12  
 alcohol use  
   action areas of, 68  
   and anhedonia in protracted withdrawal,  
     87  
   appetitiveness, 103  
   behavioral effects of, 10  
   brain mechanisms of, 71–73  
   craving studies, 98–99, 102  
   demographics of, 5  
   and dopamine, 53  
   electrophysiological markers, 89  
   and endophenotypes, 153–154  
   intoxication symptoms, 64–65  
   late positive potential (LPP), 102  
   pharmacological interventions,  
     133–135  
   and social class, 41  
   stigma of, 5  
   withdrawal symptoms, 83  
 allostatic theory, 36–38, 90–91  
 allosteric potentiator, 134  
 $\alpha$  power, 88–89  
 American Psychiatric Association (APA),  
   6  
 amotivation, 88  
 amphetamine use  
   action areas of, 66  
   behavioral addiction of, 9–10  
 amygdala volume  
   and alcohol use, 73  
   and cannabis use, 28  
   and the cue-elicited craving model,  
     40  
   and emotion regulation, 102  
 Anagnostaras, S. C., 35  
 anhedonia, 88  
 antagonists, 66  
 antireward system, 12  
 anxiety  
   and cannabis use, 41  
   and high  $\beta$  activity, 88–89  
   internet/video game addiction,  
     94  
 appetitiveness, 103–105  
 arterial spin labeling, 100  
 attention  
   and cognitive behavior therapy (CBT),  
     135  
   and craving, 105–106

- attention deficit/hyperactivity disorder (ADHD), 116–117
- Babor, T. F., 5
- backward masking, 106
- Balleine, B. W., 137
- Barratt Impulsiveness Scale, 115, 117
- Bauer, L. O., 89
- Begleiter, H., 69
- behavior prediction, 32
- behavior sensitizing experiments, 9
- behavioral addiction, 12–14
- behavioral drug treatment interventions, 135–137
- Berridge, K. C., 35
- $\beta$  power  
 and anxiety, 89–90  
 and craving, 101
- $\beta$  spectral power, 101
- Bickel, W. K., 136
- biochemical imaging, 27–28
- biomarkers, 28
- blood oxygenated level dependent (BOLD) signal, 25
- Bobzean, S. A., 156
- Boeijinga, P. H., 135
- Boileau, L., 36
- Bonson, K. R., 102
- brain  
 adolescent, 149–150  
 drug effects on mesocorticolimbic reward system, 11
- brain disease model (addiction), 2, 9–12, 130–132
- brain function  
 during protracted withdrawal, 88  
 during withdrawal, 86  
 hijacking by drugs, 104–105  
 and impulsivity, 123  
 and intoxication, 68–73  
 and love, 30  
 measurement of, 22–24
- bupropion, 134
- cannabis use  
 action areas of, 68
- behavioral effects of, 10  
 craving, 100–101  
 endocannabinoid system, 53  
 and endophenotypes, 153  
 and genetics, 29  
 longitudinal study of, 156–157  
 and perceived stress, mood, 40–41  
 and stress, 161  
 treatment outcomes, 140  
 withdrawal symptoms, 83–84
- Carroll, K. M., 134, 140
- Casey, B. J., 149
- Centers for Disease Control and Prevention (CDC), 43
- cerebral blood flow (CBF), 86
- chemical addiction, 6–12
- Childress, A. R., 102–103, 104–105
- Chocyk, A., 150
- choline, 27
- Cicero, T. J., 5
- Clark, L., 121, 123
- classical conditioning experiments, 9
- cocaine  
 action areas of, 68  
 acute withdrawal, 86  
 appetitiveness, 103  
 craving studies, 100  
 and dopamine, 52  
 during protracted withdrawal, 88  
 electrophysiological markers, 88–90  
 and the iRISA theory, 38  
 late positive potential (LPP), 102  
 pharmacological interventions, 134  
 treatment outcomes, 140  
 withdrawal symptoms, 83
- cognitive behavioral models, 135–137
- cognitive behavioral therapy (CBT), 136, 138, 140
- cognitive impairment and addiction, 12
- compulsive disorders, 12–13
- Conklin, C. A., 98
- contingency management, 136
- Corbit, J. D., 36
- Costello, M. R., 137

- craving  
 and the allostatic theory, 38  
 and attention, 105–106  
 contextual cues, 102  
 and the cue-elicited craving model, 40  
 cue-reactivity paradigms, 99–101  
 after death, 110  
 defined and research history, 98–99  
 neural mechanisms of, 101  
 neurological underpinnings of, 101–102  
 neuromolecular mechanisms, 106–107  
 and reward system hijacking, 103–105
- creatine, 27
- cue-elicited craving theory, 40
- cue-reactivity approach  
 and craving, 99  
 and methadone, 133  
 paradigms, 99–101
- Dackis, C. A., 86
- Dagher, A., 13
- Daglish, M. R., 104–105
- Decade of the Brain, 130
- delay discounting, 115, 123–125, 137
- demographics  
 and drug use, 5  
 and impulsivity, 127
- demography of addiction, 5
- dendritic alterations (brain), 106–107
- depression  
 and cannabis use, 41  
 genetic risk for, 151
- DeWitt, S., 40
- diagnosis of addiction, 6–7
- Diagnostic and Statistical Manual of Mental Disorders (DSM)*, 2, 6
- diffusivity, 25
- diffusion tensor imaging (DTI), 24
- disulfiram, 135
- Domino, E. F., 69, 88
- dopamine  
 and ADHD, 116–117  
 in behavioral activation and effort, 56  
 and craving, 100  
 and hedonistic response, 10–11  
 and hormones, 156  
 and reward learning mechanisms, 51–53  
 and the incentive-sensitization model, 35  
 and the iRISA theory, 38  
 during protracted withdrawal, 87–88  
 dopamine-depletion hypothesis, 86  
 drug classification, 66  
 Drug Enforcement Administration (DEA), 2  
 drug expectations, 75  
 drug treatment interventions  
 behavioral, 12, 135–137  
 combined approaches to, 137–139  
 legislation versus cost, 143–144  
 outcomes, 138–140  
 peer influence on, 142–143  
 pharmacological, 132–135  
 drug treatment protocol, 131–132  
 drugs (DEA schedule), 3  
 Drummond, D. C., 98  
 Ducci, F., 150, 151  
 Dunedin Multidisciplinary Health and Development Study, 156–157  
 Dunning, J. P., 102  
 dysphoria, 82
- ecological validity (craving), 99–100
- ecstasy. *See* MDMA
- effort–reward calculation, 56
- electroencephalography (EEG)  
 and alcohol endophenotypes, 153–154  
 and brain mechanism, 69  
 and craving, 101–102  
 performance of, 22–24  
 and withdrawal, 88–90
- endophenotype, 118, 150–155
- environment, 102
- enzyme-linked receptors, 66
- Ersche, K. D., 117, 118, 120, 125
- etiology of addiction, 6
- Evoy, K. E., 134
- excitatory post-synaptic potential, 22
- FBJ murine osteosarcoma viral oncogene homolog B (FosB), 106–107, 110
- Fehr, C., 85

- Feldstein Ewing, S. W., 136  
 fetal alcohol syndrome, 4  
 Filbey, F. M., 5, 13, 40–41, 100, 101, 103–104  
 final common pathway, 53–54  
 five-choice serial reaction time task (5CSRTT), 121, 125  
 food addiction, 12–13  
 fractional anisotropy, 25  
 Franken, I. H., 89, 102  
 Franklin, T. R., 100  
 functional MRI (fMRI)  
   and adolescence, 60  
   and backward masking, 105–106  
   and brain mechanism, 71–73  
   and cognitive behavioral therapy (CBT), 136  
   craving studies, 99, 133–134  
   description of, 25  
   and sex in addiction, 153
- Gallinat, J., 13, 100  
 gambling addiction, 12  
 $\gamma$ -aminobutyric acid (GABA)  
   and acamprosate, 134–135  
   and acute withdrawal symptoms, 86  
   and alcohol use, 68, 153  
   and hedonistic response, 10  
 gender and addiction, 5, 155–156  
 gene expression receptors, 66  
 genetics  
   and addiction, 5, 55–56, 150–155  
   and drug expectancy, 75  
   and impulsivity, 118  
   and limitations to neuroimaging, 29  
    $\Delta$ FosB, 106–107
- George, O., 90, 100  
 Gerbing, D. W., 115  
 Giorgio, A., 1, 149  
 Glenn, S. W., 90  
 glucose metabolism, 70–71  
 go/no go test, 119  
 Gogtay, N., 1, 2, 149  
 Gold, M. S., 85  
 Goldman, D., 150, 151  
 Goldstein, R. Z., 38, 39, 139
- Gooding, D. C., 89  
 Gould, K. L., 86  
 G protein-coupled receptor, 66  
 Gritz, E. R., 89
- half-life (substance), 82–85  
 Hariri, A. R., 150, 152  
 Hasan, K. M., 1, 149  
 hedonistic set point, 35  
 Heinze, M., 102  
 Hendriks, V. M., 102  
 heritability, 150  
 Herning, R. I., 101  
 heroin use  
   electrophysiological markers, 88  
   hijacking the brain, 105  
   late positive potential (LPP), 102  
   withdrawal symptoms, 83
- Herrmann, M. J., 102  
 Holden, C., 12  
 homeostasis, 36–38  
 Hommer, D. W., 40  
 hormones and dopamine, 156  
 hypersensitization, 35  
 hypothalamic–pituitary–adrenal axis (HPA), 90
- impaired response inhibition and salience attribution syndrome (iRISA), 38–40  
 Impulse Behavior Scale (IBS), 117  
 impulsivity  
   in adolescence, 127–128  
   defined, 114–116  
   and delaying discounting of reward, 123–125  
   and inhibitory control, 121  
   nature of, 117–120  
   neuropharmacology of, 116–117  
   and risky decision making, 120–121  
 incentive salience, 35, 47  
 incentive-sensitization theory, 34–36, 103–104  
 inhibitory control, 121, 140  
 inhibitory post-synaptic potential, 22  
*International Classification of Diseases (ICD)*, 2, 6

- internet/video game addiction  
 as behavioral addiction, 14  
 separation anxiety, 94  
 interoceptive processes, 40  
 intoxication (drug)  
 action areas of, 66–68  
 brain mechanisms of, 68–73  
 defined, 64–65  
 modulators of, 73–75  
 pharmacodynamics of, 66  
 intracranial self-stimulation experiments, 9,  
 48  
 ion channel receptors, 66  
 ionic gradients, 22  
 Iowa gambling task (IGT), 120–121
- Jarvis, M. J., 5  
 Jessie's Law, 144  
 Johnson, T. S., 134
- Kalivas, P. W., 53  
 Ketcherside, A., 41  
 Kim, J. E., 13  
 King, D. E., 88  
 Kish, S., 16  
 Knott, V. J., 88, 101  
 Kober, H., 136  
 Konova, A. B., 137, 139  
 Koob, G. F., 12, 35, 36, 37, 90–91  
 Kourosch, A. S., 13  
 Kuczenski, R., 9  
 Kuhn, S., 13, 100
- Landes, R. D., 136  
 late positive potential (LPP), 102  
 Le Moal, M., 35, 36, 37, 90–91  
 Lebel, C., 1, 149  
 Leith, N. J., 9  
 Lenoir, M., 12  
 Lewis, C. C., 136  
 ligands, 66  
 limbic cortex activation, 102  
 Littel, M., 89  
 Liu, X., 101  
 Loughhead, J., 133  
 love and brain function, 30
- LSD (lysergic acid diethylamide), 15, 66  
 magnetic resonance imaging (MRI), 12,  
 24–27  
 magnetic resonance spectroscopy (MRS),  
 27  
 magnetoencephalography (MEG), 22–23  
 Marijuana Problem Scale (MPS), 101  
 Martinotti, G., 87  
 masked cue task, 105–106  
 McDonough, B. E., 102  
 MDMA (3,4-  
 methylenedioxyamphetamine),  
 15, 66  
 mechanisms of addiction, 9–12  
 memory and addiction, 56–58  
 mental disorders and addiction, 4  
 mesolimbic reward system (brain)  
 and behavioral addiction, 13–14  
 changes during addiction, 10–12  
 and the cue-elicited craving model, 40  
 as reward system, 49  
 metabolites (brain tissue), 27  
 methadone, 133  
 methamphetamine use, 53  
 monetary incentive delay task, 60  
 morphine, 9  
 motivation  
 and future drug use prediction, 60  
 and reward learning mechanisms, 47–58  
 motivational enhancement therapy (MET),  
 136  
 motivational interviewing (MI), 136, 138  
 Myrick, H., 100, 101
- N*-acetylaspartate (NAA), 27  
 Namkoong, K., 102  
 National Institutes of Health (NIH), 31  
 natural reinforcers, 12  
 neonatal abstinence syndrome, 4, 93  
 Nestler, E. J., 106  
 neuroimaging studies  
 and addiction activity, 12  
 and behavior prediction, 32  
 craving, 99–101  
 diffusion tensor imaging (DTI), 24

- neuroimaging studies (cont.)  
 electroencephalography (EEG), 22–24,  
 69, 88–90, 101–102, 153–154  
 functional MRI (fMRI), 25, 60, 71–73, 99,  
 105–106, 133–134, 136, 153  
 and impulsivity, 119  
 limitations of, 28–29  
 magnetic resonance imaging (MRI),  
 24–27  
 magnetic resonance spectroscopy (MRS),  
 27  
 magnetoencephalography (MEG), 22–23  
 of behavioral addiction, 13–14  
 of combined drug interventions, 137–138  
 positron emission tomography (PET), 12,  
 26–28, 52–53, 69–71, 100  
 single-photon emission computed  
 tomography (SPECT), 26, 27–28  
 structural MRI, 24
- Niaura, R. S., 98
- nicotine use  
 action areas of, 66–68  
 and brain mechanism, 68–70  
 and craving, 100, 101–102  
 and the cholinergic system, 53  
 delay discounting, 124  
 demographics of, 5  
 pharmacological interventions, 133–134  
 and social class, 41  
 withdrawal symptoms, 83, 87
- nucleus accumbens  
 and acute withdrawal symptoms, 86  
 and ADHD, 116–117  
 as common addiction pathway, 54  
 and craving, 106–107, 109  
 and dopamine, 49–52
- Nutt, D. J., 104
- O'Brien, C. P., 13
- Ogawa, S., 25
- opioid use  
 action areas of, 68  
 addiction from birth, 93  
 behavioral effects of, 10  
 demographics of, 5  
 and hedonistic response, 11  
 and the opioid system, 53  
 pharmacological interventions, 133  
 as public health concern, 43–45, 162  
 treatment cost, 143–144
- opponent-process theory, 36, 90–91
- Orsini, C., 82
- P300, 101–102
- Pagliari, D., 28
- Papageorgiou, C. C., 89
- Pavlovian conditioning, 98–99
- peer recovery specialists, 142–143
- pharmacodynamics, 66
- pharmacological interventions, 132–135
- phencyclidine (PCP), 68
- phenomenology of addiction, 4
- place preference, 9–10
- pleasure molecule. *See* dopamine
- Porjesz, B., 69, 89, 153, 154
- positron emission tomography (PET)  
 and brain mechanism, 69–71  
 craving studies, 100  
 dopamine studies, 27–28, 53  
 post-acute withdrawal syndrome, 87–88
- post-traumatic stress disorder (PTSD),  
 15–16, 161
- Potenza, M. N., 137–138
- prefrontal cortex  
 and craving, 100, 106–107  
 and decision making, 120–121  
 and dopamine, 51–53  
 during withdrawal, 86  
 dysfunction and relapse, 85–86  
 and the iRISA theory, 38–39  
 and reinstatement, 54
- pre-potent response, 115
- probability discounting, 124
- Probst, C. C., 12
- protracted withdrawal symptoms, 87–88
- psychedelic drug therapeutic benefits,  
 15–16
- psychiatric disorders and addiction, 5
- pyramidal cells, 22
- radionucleotides, 27
- radiotracer, 100

- Rangaswamy, M., 153, 154  
 receptors, 66  
 Reid, M. S., 101  
 reinstatement experiments  
   and drug relapse, 9  
   and final common pathway, 53–54  
 relapse prediction  
   for drug-addicted patients, 131  
   electrophysical makers for, 89–90  
   prefrontal cortex and, 85–86  
   reinstatement experiments, 10  
 relapse prevention, 140  
 resting-state functional connectivity (rsFC),  
   71  
 reward deficiency syndrome, 55  
 reward system  
   and addiction, 10–12  
   and behavioral-drug treatment  
     interventions, 137  
   and craving, 103–105  
   and incentive salience, 35  
   and motivation, 47–58  
 risk factors, 5, 149–150  
 risky decision making, 120–121  
 Robinson, T. E., 35, 50, 99  
 Roemer, R. A., 88
- Salamone, J. D., 56, 57  
 Schacht, J. P., 28, 153, 155  
 Schedule I drugs, 2–3  
 Schneider, F., 99  
 school dropout rate and addiction, 4  
 Sell, L. A., 104  
 Seltenhammer, M., 109  
 serotonin, 68  
 sex addiction  
   appetitiveness, 103–104  
   as behavioral addiction, 12–13  
 Shaw, P., 1, 150  
 shopping addiction, 13  
 Shufman, E., 88  
 single-photon emission computed  
   spectroscopy (SPECT), 27–28,  
   69  
 Sinha, R., 86  
 Skinner, M. D., 135
- social class  
   and addiction, 5  
   and drug use, 41  
 Sofuoglu, M., 134, 137  
 Solomon, R. L., 36  
 stimulant use  
   behavioral effects of, 10  
   demographics of, 5  
 stop signal reaction time (SSRT), 119, 121,  
   123  
 stress (adolescent), 150, 161  
 structural MRI, 24  
 substance use disorder (SUD)  
   addiction as, 2  
   behavioral symptoms of, 12–13  
   classification systems of, 6–7  
 sugar addiction, 12–13  
 superconducting quantum interference  
   device (SQUID), 22  
 Surwillo, W. W., 88  
 sympathomimetic action, 86
- Tanabe, J., 86, 87  
 tanning addiction, 12, 13  
 Teklezgi, B. G., 133  
 tetrahydrocannabinol (THC), 68  
 thalamus, 86  
 Tiffany, S. T., 98–99, 105  
 tolerance  
   and the allostatic theory, 36–38  
   brain adaptation and, 11  
   and substance use, 4  
   sugar, 12–13  
 tractography, 25  
 transduction, 66
- unemployment rate and addiction, 4
- Vaituzis, A. C., 1, 150  
 van de Laar, M. C., 102  
 van Eimeren, T., 12  
 Venables, P. H., 88  
 Verdejo-Garcia, A., 140  
 Vogeler, T., 134  
 Volkow, N. D., 13, 38, 39, 40, 52, 53–54, 71,  
   75, 85, 86, 88

- wait circuit, 124  
 waiting, 125  
 Wang, G. J., 71  
 Warren, C. A., 102  
 Weeks, J. R., 9  
 Wexler, B. E., 136  
 Wierenga, L. M., 150  
 Winterer, G., 89  
 withdrawal  
   acute, 85–86  
   and the allostatic theory, 36  
   between systems adaptations, 90–91  
   brain adaptation and, 11  
   brain function during, 86  
   and dark side of addiction, 11  
   defined, 81–82  
   electrophysiological mechanisms of, 88–90  
   and incentive sensitization model, 35  
   and the iRISA theory, 39  
   protracted, 87–88  
   and substance use, 4  
   sugar, 12  
   symptoms and classification of,  
     82–84  
 Wong, D. F., 100  
 Worhunsky, P. D., 13  
 World Health Organization, 2, 6  
 Wrase, J., 99  
 Wray, J. M., 105  
 young adult. *See* adolescence  
 Young, K. A., 105  
 Zubieta, J. K., 86